Xenetic Biosciences
Biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens.
Launch date
Employees
Market cap
$6.2m
Enterprise valuation
($1m) (Public information from Sep 2024)
Share price
$3.75 XBIO
Company register number 03213174
London England (HQ)
Authorizing premium user...